Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...
Each year the CHS honours individuals who have made a significant contribution to improving the quality of life of people with bleeding disorders. The 2023...
HIV Justice News published the following on October 28: “The past two weeks has seen some important HIV Justice advances in three countries – Canada,...
The tainted blood tragedy is incontestably the worst public health disaster that Canada has ever faced. Today, October 27, anniversary of the creation of the...
